In the context of patients with known mutations in BRCA1 or BRCA2, the phase II basket study (MEDIOLA) evaluated combination of durvalumab (anti-PD-L1) and olaparib in 32 patients with platinum-sensitive relapsed ovarian cancer (21). This evidence concerns the gene BRCA1 and ovarian carcinoma.